- Correction
- Open access
- Published:
Correction: GlucoMedix®, an extract of Stevia rebaudiana and Uncaria tomentosa, reduces hyperglycemia, hyperlipidemia, and hypertension in rat models without toxicity: a treatment for metabolic syndrome
BMC Complementary Medicine and Therapies volume 22, Article number: 230 (2022)
The Original Article was published on 08 March 2022
Correction: BMC Complement Med Ther 22, 62 (2022)
https://doi.org/10.1186/s12906-022-03538-9
Following publication of the original article [1], the authors reported an error in Table 8 and Fig. 8.
The Table 8 reported for the glucose levels (Alloxan-induced) of GlucoMedix® treatments was incorrect. However, the correct data set reveals that the results are similar to those reported. The percentage of the chemically induced maximum level minus the uninduced level at 28 days (as displayed in Fig. 8) is 62.0 % at 250 mg/kg (vs 36.4 % as reported), 16.3 % at 500 mg/kg (vs 13.5 % as reported), and 0.8 % at 1,000 mg/kg (vs -2.6 % as reported), and the Glibenclamide 10 mg/kg positive control should be -1.2 % (vs -5.6 % as reported). Thus, the IC50 value for glucose levels with GlucoMedix® is between 250 and 500 mg/kg (vs < 250 mg/kg as reported). Furthermore, the number of animals per group for the glucose and lipid profile experiments was five (vs seven as reported).
Dose response for oral GlucoMedix® in rat models. GlucoMedix® (250, 500, 1000 mg/kg) treatment effects, expressed as the percentage of the chemically induced maximum minus the uninduced baseline; glucose at 28 days; cholesterol and triglycerides at 21 days; systolic, diastolic, and mean BP at 28 days
The original article [1] has been updated.
Reference
Villegas Vílchez LF, Ascencios JH, Dooley TP. GlucoMedix®, an extract of Stevia rebaudiana and Uncaria tomentosa, reduces hyperglycemia, hyperlipidemia, and hypertension in rat models without toxicity: a treatment for metabolic syndrome. BMC Complement Med Ther. 2022;22:62. https://doi.org/10.1186/s12906-022-03538-9.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Villegas Vílchez, L.F., Ascencios, J.H. & Dooley, T.P. Correction: GlucoMedix®, an extract of Stevia rebaudiana and Uncaria tomentosa, reduces hyperglycemia, hyperlipidemia, and hypertension in rat models without toxicity: a treatment for metabolic syndrome. BMC Complement Med Ther 22, 230 (2022). https://doi.org/10.1186/s12906-022-03708-9
Published:
DOI: https://doi.org/10.1186/s12906-022-03708-9